Shares of Bioventix PLC (LON:BVXP - Get Free Report) crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of GBX 2,713.11 ($36.42) and traded as high as GBX 2,800 ($37.59). Bioventix shares last traded at GBX 2,655 ($35.64), with a volume of 1,838 shares.
Bioventix Price Performance
The firm has a market cap of £137.09 million, a PE ratio of 16.93 and a beta of 0.35. The stock has a 50-day moving average price of GBX 2,719.27 and a 200 day moving average price of GBX 2,924.91.
Bioventix (LON:BVXP - Get Free Report) last issued its quarterly earnings results on Monday, March 31st. The biotechnology company reported GBX 72.27 ($0.97) earnings per share (EPS) for the quarter. Bioventix had a return on equity of 69.09% and a net margin of 59.51%. As a group, equities research analysts anticipate that Bioventix PLC will post 166.3066955 earnings per share for the current year.
Bioventix Cuts Dividend
The business also recently announced a dividend, which was paid on Friday, April 25th. Investors of record on Thursday, April 10th were given a GBX 70 ($0.94) dividend. The ex-dividend date was Thursday, April 10th. This represents a dividend yield of 2.95%. Bioventix's dividend payout ratio is presently 102.19%.
Insider Activity at Bioventix
In other news, insider Bruce Hiscock bought 31 shares of the business's stock in a transaction that occurred on Monday, April 28th. The shares were acquired at an average cost of GBX 2,632 ($35.33) per share, with a total value of £815.92 ($1,095.34). 8.02% of the stock is owned by insiders.
About Bioventix
(
Get Free Report)
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants.
See Also
Before you consider Bioventix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventix wasn't on the list.
While Bioventix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
